secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001935979-23-000064
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven Q3 net loss $102.6M ($1.50/share); cash $495M after public offering; pipeline advances
--------------------------------------------------------------------------------

- Net loss of $102.6M ($1.50/share) vs $68.9M ($1.75/share) in Q3 2022; non-GAAP adjusted net loss $98.1M ($1.44/share).
- Cash, cash equivalents and securities $495M as of Oct 5, 2023, including $242M net from public offering of 11.76M shares at $22.
- BHV-1300 IgG degrader showed >90% IgG reduction in non-human primates; IND submission on track for 2023.
- BHV-7000 Phase 1 EEG study confirmed CNS target engagement; Phase 3 focal epilepsy trial to start in 2023.
- Completed enrollment in Phase 3 study of taldefgrobep alfa in SMA; troriluzole MAA under EMA review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597923000064/0001935979-23-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597923000064/bhvn-20231114.htm
  HTML page:      https://secwatch.observer/filing/0001935979-23-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer